The AKT Pathway in Ovarian Cancer — Sloan-Kettering
Identifying the genetic factors that contribute to ovarian cancer may lead to the development of more effective therapies, says Dr. David Solit, a medical oncologist at Memorial Sloan-Kettering Cancer Center. About 50% of ovarian cancer patients have mutations that affect AKT, an enzyme that promotes tumor growth. Identifying patients with this mutation will be key in determining the effectiveness of new medications that selectively block AKT. For more information, please visit www.mskcc.org